NRAS and melanoma: The clinically characterized tumor molecular subtypes included BRAF, NRAS, KRAS, KIT, and PIK3CA mutant melanomas, with BRAF mutant melanomas being more prevalent in AYA compared to adult patients (77% vs 41%; Fisher’s exact test, P = 0.0003).